SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biosource International -- Ignore unavailable to you. Want to Upgrade?


To: tom pope who wrote (514)7/7/1998 7:35:00 PM
From: Rich Powers  Respond to of 696
 
Tom,

Zacks says earnings are to be reported on 7/27/98. Analysts like the stock and Zacks gives it a moderate buy rating. Earnings are expected to be $.11 a share. They are also looking for $.11 a share next quarter--not a lot to look forward to, but if they beat the $.11 and have a positive analyst telecon, the September estimate is likely to be revised upward.

I know it has a great long term future because Joe Dancy likes it. I don't think it it a candidate for trading. Comments, Joe?

Regards,

Rich



To: tom pope who wrote (514)7/7/1998 9:29:00 PM
From: Joe Dancy  Read Replies (1) | Respond to of 696
 
Not sure when 2Q will be issued Tom. Yeah, with the meeting on June 22nd and Chamberlain - the CEO and Pres - saying as he explained one of his charts that he expected revenue increases again this quarter made me feel a little more comfortable with what type of earnings they will report.

I have not looked at Zack's for a consensus, but I remember the last conference call BIOI management said they felt comfortable with earnings for the year in the mid-40 cent range or even higher with the buyback. No upgrades or downgrades I've heard of - of course they will probably upgrade if the stock hits $12 or downgrade if the stock hits $2.

If you put the pencil to it that would mean a p/e on this years earnings of around 13. Pretty undervalued for a company that should grow earnings around 20% a year in my conservative estimate - and more like 30% a year if you believe the analysts.

Solid balance sheet, growing revenues, growing industry - after hearing the company presentation I had to restrain myself from buying more - I really like these people.

Joe